MTDH and hepatocellular carcinoma: Although briefly, these experiments did suggest that AEG-1 palmitoylation might be a valuable pharmaceutical target and further, increasing AEG-1 palmitoylation by HCQ might confer therapeutic benefits for HCC patients in clinics, which warrants future investigations.